Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.

Adjuvant chemotherapy does not improve survival in node-positive luminal A breast cancer

12 Jul 2017

Endocrine therapy alone may decrease morbidity in node-positive, luminal A breast cancer patients, a new retrospective study shows. Adjuvant chemotherapy, on the other hand, may confer only minimal benefits.

There was no significant difference in the overall survival of node-positive, luminal A breast cancer patients who received endocrine therapy alone (n=50; median age 58.7±11.7 years) and those who received adjuvant chemotherapy (n=642; median age 58.3±9.5 years;hazard ratio [HR], 4.565; 95 percent CI, 0.59 to 40.947; p=0.175).

In contrast, pathologic node stage (HR, 3.715; 0.807 to 17.106; p=0.092) and progesterone receptor (PR) status (HR, 8.627; 1.646 to 45.216; p=0.011) were both associated with overall survival, according to multivariable analysis.

Similarly, adjuvant chemotherapy did not significantly impact disease-free survival (DFS) in node-positive luminal A breast cancer patients (HR, 2.420; 0.554 to 1.0567; p=0.240). On the other hand, nuclear grade (p=0.032), PR status (p=0.001) and radiotherapy (p=0.025) all significantly influenced DFS.

The 50 women on endocrine therapy alone were matched by propensity score to a maximum of 8 women who received adjuvant chemotherapy, yielding a comparison group of 642. There were no significant differences between the groups in terms of demographic factors, tumour factors and pathologic findings.

Patients receiving treatment for invasive breast cancer were recruited from the Samsung Medical Centre. Tamoxifen or aromatase inhibitors were used for the endocrine therapy. Adjuvant chemotherapy included regimens such as doxorubicin with cyclophosphamide, paclitaxel, docetaxel and 5-fluorouracil.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.